Elite in Undifferentiated Connective Tissue Disease (UCTD)

Michele D'alto

Naples, IT 
Elite in Undifferentiated Connective Tissue Disease (UCTD)
Naples, IT 
OverviewLocationsClinical Research

Overview

Michele D'alto practices in Naples, Italy. D'alto is rated as an Elite expert by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Their top areas of expertise are Eisenmenger Syndrome, Pulmonary Hypertension, Hypertension, Undifferentiated Connective Tissue Disease (UCTD), and Heart Transplant.

Their clinical research consists of co-authoring 172 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Undifferentiated Connective Tissue Disease (UCTD).

Locations

Naples, Italy
Other Locations
Via Bianchi 6, Via, 80131, Italy
Pavia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension
A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Drugs: Tadalafil, ERA as specific PAH treatment
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

172 Total Publications

Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study.
Economic and Social Burden of Pulmonary Arterial Hypertension in Italy: A Cost-of-Illness Study.
Journal: Drugs - real world outcomes
Published: September 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find D'alto's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile